Insider trade

Dermata Therapeutics (DRMA): CEO received 1.36M units

Gerald T Proehl, CEO at Dermata Therapeutics, reported a grant / award of 1.36M units.

1.36M
Derivative units
Traded
Aug 16, 2026
Filed
Aug 18, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Aug 11, 2026Company filing · Form 8-K · ResultsReported its results
  2. Aug 16, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)

What came next

  1. Nov 2, 20265% stakeBigger Michael reported a passive stake (13G) of 8.4%
  2. Nov 10, 2026Company filing · Form 8-K · ResultsReported its results
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Dermata Therapeutics

For Dermata Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DRMA page.

How this filing works

Explore the data

Common questions

Which Dermata Therapeutics (DRMA) insider traded, and how much?

Gerald T Proehl, CEO at Dermata Therapeutics, reported a grant / award of 1.36M units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Aug 16, 2026. Filed: Aug 18, 2026. That is 2 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Dermata Therapeutics recently?

For Dermata Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the DRMA page.

Does this mean DRMA stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Dermata Therapeutics

Everything OQRO holds on this company is on its DRMA page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data